Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges.

Synthetic antisense oligonucleotides (ASOs) and duplex RNAs (dsRNAs) are an increasingly successful strategy for drug development. After a slow start, the pace of success has accelerated since the approval of Spinraza (nusinersen) in 2016 with several drug approvals. These accomplishments have been achieved even though oligonucleotides are large, negatively charged, and have little resemblance to traditional small-molecule drugs-a remarkable achievement of basic and applied science. The goal of this review is to summarize the foundation underlying recent progress and describe ongoing research programs that may increase the scope and impact of oligonucleotide therapeutics. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Cristina R Hofman, David R Corey. Targeting RNA with synthetic oligonucleotides: Clinical success invites new challenges. Cell chemical biology. 2024 Jan 18;31(1):125-138

Mesh Tags

Substances

PMID: 37804835

search → result